Sandbox: m: Difference between revisions
Jump to navigation
Jump to search
Created page with "{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" |valign=top| |+ ! style="background: #4479BA; width: 250px; color: #FFFFFF;"|'''Prognostic Factor''' ! styl..." |
No edit summary |
||
Line 1: | Line 1: | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: | {| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" | ||
|valign=top| | |valign=top| | ||
|+ | |+ '''Cardiac Myxoma''' | ||
! style="background: #4479BA; width: | ! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''Features''' | ||
! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Description''' | ! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Description''' | ||
Line 8: | Line 8: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | ''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''General aspects'''|| style="padding: 5px 5px; background: #F5F5F5;" | | ||
:* Older age at the time of diagnosis is associated with a worse prognosis. | :* Older age at the time of diagnosis is associated with a worse prognosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | ''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetics'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:* Males are associated with a worse prognosis when compared to females. | :* Males are associated with a worse prognosis when compared to females. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | ''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gross Pathology'''|| style="padding: 5px 5px; background: #F5F5F5;"| | ||
:* Patient's poor [[performance status]] is associated with a worse prognosis. | :* Patient's poor [[performance status]] is associated with a worse prognosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | ''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Micropathology'''|| style="padding: 5px 5px; background: #F5F5F5;" | | ||
:*Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis. | :*Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | ''' | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Inmunohistochemistry'''|| style="padding: 5px 5px; background: #F5F5F5;" | | ||
:*A rapid [[lymphocyte]] doubling time is associated with a worse prognosis. | :*A rapid [[lymphocyte]] doubling time is associated with a worse prognosis. | ||
|} | |} |
Revision as of 21:36, 23 November 2015
Features | Description |
---|---|
General aspects |
|
Genetics |
|
Gross Pathology |
|
Micropathology |
|
Inmunohistochemistry |
|